Selective PI3Kδ Inhibitors for Autoimmune Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K inhibitors, such as wortmannin and LY294002, are non-specific, making it difficult to distinguish between different PI3K isoforms and understand their individual roles in cellular processes and diseases, particularly in inflammatory and autoimmune settings.
Innovation Solution
Development of new compounds with a specific structure that selectively inhibit PI3Kδ while having low inhibitory potency against other PI3K isoforms, allowing for the characterization of PI3Kδ function and modulation of its activity to treat diseases mediated by PI3Kδ dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If non-specific PI3K inhibitors (wortmannin, LY294002) are used, then PI3K activity is inhibited, but it becomes difficult to distinguish between different PI3K isoforms and understand their individual roles
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular structures (formula I compounds) that are tailored to interact with a particular PI3K isoform (e.g., PI3Kδ) rather than binding equally to all isoforms. The inhibitors exhibit selective binding affinity and pharmacological activity against specific isoforms, enabling differentiation of isoform-specific functions while avoiding non-specific inhibition of other PI3K family members.
2Reliability
If selective PI3Kδ inhibitors are developed, then PI3Kδ function can be characterized and targeted therapy can be achieved, but the complexity of compound structure and synthesis increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of the inhibitor compounds (formula I structure) including substituent groups (R1-R6, X1-X8, Y, n values) to optimize selectivity for PI3Kδ. By varying these chemical parameters, the compounds achieve high therapeutic specificity while maintaining manageable structural complexity through established medicinal chemistry design frameworks.
3Loss of information
If existing PI3K inhibitors are used, then broad PI3K activity is suppressed, but individual isoform roles in inflammatory and autoimmune conditions cannot be distinguished
Solution Approach 1:
The patent applies segmentation by dividing the PI3K inhibition function into isoform-specific activities. Instead of using a single non-specific inhibitor that suppresses all PI3K isoforms simultaneously, the invention develops a series of segmented inhibitors (formula I compounds) that can be selectively active against specific isoforms (e.g., PI3Kδ, PI3Kα, PI3Kβ). This segmentation enables independent characterization of each isoform's role in inflammatory and autoimmune conditions while maintaining overall PI3K inhibition capability when needed.
Data Source
AI summary
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.